


14th International Workshop on
MULTIPLE ENDOCRINE NEOPLASIA
and other rare endocrine tumors

September 25 – 27, 2014
Vienna, Austria

www.worldmen2014.at



PROGRAM



	Registration Area	Exhibition Area / Catering Area	Poster Area	Lecture Room
09:00 - 09:30	Exhibitors Service Desk 09:00 - 12:00 Registration Desk 14:00 - 18:00	Build up of Exhibition		
09:30 - 10:00				
10:00 - 10:30			Build up of Poster Walls	
10:30 - 11:00				
11:00 - 11:30				
11:30 - 12:00				
12:00 - 12:30				
12:30 - 13:00				
13:00 - 13:30				
13:30 - 14:00				
14:00 - 14:30				
14:30 - 15:00				
15:00 - 15:30				
15:30 - 16:00				
16:00 - 16:30		Exhibition	Poster mounting	Session 1: Genetic aspects of pituitary tumors Educational Invited Lectures S1.1 - S 1.6 Free Paper FP1.1
16:30 - 17:00			Poster on Display	
17:00 - 17:45				
17:45 - 18:15				Opening Ceremony incl. World Men Awards 2014
18:15 - 19:00				
19:00 - 19:30			Poster-discussion	Welcome Reception and Poster Party
19:30 - 20:00				



	Registration Area	Exhibition Area / Catering Area	Poster Area	Lecture Room
07:00 - 07:30				
07:30 - 08:00	Registration Desk & Exhibitor Service Desk 07:30 - 18:00			
08:00 - 08:30		Exhibition	Poster on display	Session 2: MEN 1 and hyperparathyroid syndromes Invited Lectures S2.1 - S2.6 Free Paper FP2.1
08:30 - 09:00				
09:00 - 09:30				
09:30 - 09:50				
09:50 - 10:00				
10:00 - 10:20				
10:20 - 10:40		Coffee Break (in Exhibition Area)		
10:40 - 11:30		Exhibition	Poster on display	Session 3: MEN 1 and the pancreas Invited Lectures S3.1 - S3.7 Free Paper: FP3.1 & FP3.2
11:30 - 12:00				
12:00 - 12:30				
12:30 - 12:40				
12:40 - 13:00		Break		
13:00 - 13:30		Exhibition	Poster on display	Lunch Symposium: Medical treatment of advanced neuroendocrine pancreatic neoplasia LS1.1 - LS1.4
13:30 - 14:00				
14:00 - 14:10				
14:10 - 14:30		Exhibition	Poster on display	Session 4: Selected Case Presentations CP4.1 - CP4.5
14:30 - 15:00				
15:00 - 15:25				Jakob Erdheim Honorary Lecture L2.2
15:25 - 15:30		Break		
15:30 - 16:00		Exhibition	Poster on display	Session 5: MEN 2 and rare RET mutations / Medullary thyroid cancer Invited Lectures S5.1 - S5.6 Free Papers FP5.1 - FP5.4
16:00 - 16:30				
16:30 - 17:00				
17:00 - 17:30				
17:30 - 17:50				
17:50 - 18:30		Coffee Break (in Exhibition Area)		
18:30 - 19:00		Exhibition	Poster on display	Session 6: New experimental and clinical developments Invited Lectures S6.1 - S6.3, Free Papers FP6.1 & FP6.2
19:00 - 20:00				
20:00 - 23:00	Evening Event *			

* more information please find on page 38 Events / Social Program



	Registration Area	Exhibition Area / Catering Area	Poster Area	Lecture Room
07:00 - 07:30				
07:30 - 08:00				
08:00 - 08:30				
08:30 - 09:00				
09:00 - 09:30				
09:30 - 10:00				
10:00 - 10:30				
10:30 - 11:00				
11:00 - 11:30				
11:30 - 12:00				
12:00 - 12:30				
12:30 - 13:00				
13:00 - 13:30				
13:30 - 14:00				
14:00 - 14:30				
14:30 - 15:00				
15:00 - 15:30				
15:30 - 16:00				
16:00 - 16:30				
16:30 - 17:00				
17:00 - 17:30				

Registration Area

Exhibition Area / Catering Area

Poster Area

Lecture Room

07:00 - 07:30

07:30 - 08:00

08:00 - 08:30

08:30 - 09:00

09:00 - 09:30

09:30 - 10:00

10:00 - 10:30

10:30 - 11:00

11:00 - 11:30

11:30 - 12:00

12:00 - 12:30

12:30 - 13:00

13:00 - 13:30

13:30 - 14:00

14:00 - 14:30

14:30 - 15:00

15:00 - 15:30

15:30 - 16:00

16:00 - 16:30

16:30 - 17:00

17:00 - 17:30

Registration Desk & Exhibitor Service Desk
07:30 - 15:00

Exhibition

Poster on display

Session 7: Treatment of advanced endocrine tumors
Educational Invited Lectures S7.1 - S7.4
Free Papers FP7.1 - FP7.3

Coffee Break (in Exhibition Area)

Exhibition

Poster on display

Session 8: Selected Poster presentation
Posters: SP8.1 - SP8.6

Session 9: Hereditary pheochromocytoma and paraganglioma
Educational Invited Lectures S9.1 - S9.5
Free Papers FP9.1 & FP9.2

**Closing Ceremony
Poster Award
Best Presentation Award**

Farewell

Dismantling of Exhibition & Poster Walls



	Registration Area	Exhibition Area / Catering Area	Poster Area	Lecture Room
07:00 - 07:30				
07:30 - 08:00	Registration Desk & Exhibitor Service Desk 07:30 - 15:00			
08:00 - 08:30		Exhibition	Poster on display	Session 7: Treatment of advanced endocrine tumors Educational Invited Lectures S7.1 - S7.4 Free Papers FP7.1 - FP7.3
08:30 - 09:00				
09:00 - 09:30				
09:30 - 10:00				
10:00 - 10:30				
10:30 - 11:00		Coffee Break (in Exhibition Area)		
11:00 - 11:30		Exhibition	Poster on display	Session 8: Selected Poster presentation Posters: SP8.1 - SP8.6
11:30 - 12:00				Session 9: Hereditary pheochromocytoma and paraganglioma Educational Invited Lectures S9.1 - S9.5 Free Papers FP9.1 & FP9.2
12:00 - 12:30				
12:30 - 13:00				
13:00 - 13:30				
13:30 - 14:00	Closing Ceremony Poster Award Best Presentation Award			
14:00 - 14:30	Farewell			
14:30 - 15:00	Dismantling of Exhibition & Poster Walls			
15:00 - 15:30				
15:30 - 16:00				
16:00 - 16:30				
16:30 - 17:00				
17:00 - 17:30				



Chair		A. Daly (Liège) M.L. Jaffrain-Rea (Italy) A. Luger (Austria)
16:00 – 17:45		Session 1 Genetic aspects of pituitary tumors
S1.1	15 min (10+5)	Clinical and genetic aspects of familial isolated pituitary adenomas <i>A. Beckers (Belgium)</i>
S1.2	15 min (10+5)	How AIP mutations cause aggressive pituitary adenomas <i>A. Karhu (Finland)</i>
S1.3	15 min (10+5)	Micro-RNAs in pituitary adenoma pathology: culprits or bystanders? <i>M.C. Zatelli (Italy)</i>
S1.4	15 min (10+5)	Pituitary gland in MEN 1 syndrome: from histo-pathology to prognosis <i>C. Villa (France)</i>
S1.5	15 min (10+5)	Clinical features and therapeutic outcomes in aggressive pituitary adenomas and carcinomas <i>G. Raverot (France)</i>
S1.6	15 min (10+5)	What we know and don't know about the pathophysiology of MEN 1 pituitary adenomas <i>S. Agarwal (USA)</i>
FP1.1	10 min (7+3)	Absence of GNAS1 mutations in somatotropinomas from AIPmut positive patients: possible implications for phenotype. <i>M. Korbonits (United Kingdom)</i>
17:45 – 18:15		Opening Ceremony * incl. World Men Awards 2014
18:15 – 20:00		Welcome Reception / Poster Party *

* for detailed information please see page 28



Chair		M.L. Brandi (Italy) O.A. Haas (Austria) R.V. Thakker (United Kingdom)
08:00 – 09:50		Session 2 MEN 1 and hyperparathyroid syndromes
S2.1	5 min	Introduction FIRMO Parathyroid Medal to E.M. Brown M.L. Brandi (Italy)
S2.2	25 min (20+5)	The calcium sensing receptor (CaSR) and disordered of Ca²⁺-sensing: from the gene to the patient E.M. Brown (USA)
S2.3	20 min (15+5)	Genetics of parathyroid tumors R.V. Thakker (United Kingdom)
S2.4	20 min (15+5)	Medical Management of primary hyperparathyroidism M.L. Brandi (Italy)
S2.5	20 min (15+5)	Management of primary hyperparathyroidism in pregnancy: why and when? R. Eastell (United Kingdom)
FP2.1	10 min (7+3)	Treatment of children with Neonatal Severe Hyperparathyroidism (NSHPT) T.R. Kurzwinski (United Kingdom)
S2.6	10 min (7+3)	Hyperparathyroidism - Jaw Tumor Syndrome: current aspects in diagnosis and treatment M. Iacobone (Italy)
09:50 - 10:20		Historical Lecture
L1.1	5 min	Introduction B. Niederle (Austria)
L1.2	20 min	Jakob Erdheim (1874-1937) – pioneer of endocrine pathology H. Swoboda (Austria)
10:20 - 10:40		Coffee break



Chair		G. Akerström (Sweden) H. Dralle (Germany) M. Falconi (Italy)
10:40 – 12:40		Session 3 MEN 1 and the pancreas Under the auspices of the European Society of Endocrine Surgeons (ESES)
S3.1	15 min (10+5)	Indication for surgery in MEN 1 neuroendocrine pancreatic tumors: Biology <i>A. Perren (Switzerland)</i>
S3.2	15 min (10+5)	Indication for surgery in MEN 1 neuroendocrine pancreatic tumors: Size <i>F. Triponez (Switzerland)</i>
S3.3	10 min (7+3)	Indication for surgery in MEN 1 neuroendocrine pancreatic tumors: Molecular genetic aspects <i>P. Goudet (France)</i>
FP3.1	10 min (7+3)	Higher risk of aggressive pancreatic neuroendocrine tumors in MEN 1 patients with mutations affecting the CHES1 interacting domain of the MEN 1 gene <i>J. Waldmann (Germany)</i>
FP3.2	10 min (7+3)	Should 68Gallium-DOTATATE PET/CT be the first-line imaging study to detect neuroendocrine tumors in patients with multiple endocrine neoplasia type 1? <i>S. Sadowski (USA)</i>
S3.4	15 min (10+5)	Resection (Thompson procedure) or total pancreatectomy, asymptomatic tumors <i>G. Doherty (USA)</i>
S3.5	15 min (10+5)	Surgical concepts of MEN 1 gastrinoma <i>D.K. Bartsch (Germany)</i>
S3.6	15 min (10+5)	Clinical features and surgical management of MEN 1 insulinomas <i>F. Tonelli (Italy)</i>
S3.7	15 min (10+5)	Is laparoscopic surgery in patients with neuroendocrine pancreatic tumors associated with multiple endocrine neoplasia type 1 adequate? <i>L. Fernández-Cruz (Spain)</i>
12:40 – 13:00		Break



Chair	K. Öberg (Sweden) M. Pavel (Germany)
13:00 – 14:00	Lunch Symposium Medical treatment of advanced neuroendocrine pancreatic neoplasia Under the auspices of the European Neuroendocrine Tumor Society (ENETS)
LS1.1 15 min (10+5)	Molecular subtypes of pancreatic neuroendocrine tumors and their distinct phenotypes <i>A. Sadanandam (United Kingdom)</i>
LS1.2 15 min (10+5)	Somatostatin analogs – what do we learn from the current clinical trials? <i>M. Raderer (Austria)</i>
	Integration of targeted- therapy into treatment regimens: Sunitinib and Everolimus - Competition or completion
LS1.3 15 min (10+5)	Sunitinib in the treatment of advanced pancreatic neuroendocrine tumors – current data <i>E. Raymond (France)</i>
LS1.4 15 min (10+5)	Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience <i>J.C. Yao (USA)</i>

14:00 – 14:10 Break



Chair	C. Bichler (Austria) C. Scheuba (Austria)
14:10 – 15:00	Session 4 Selected Case Presentations
CP4.1 10 min (7+3)	Five families with RET-mutation negative familial medullary thyroid carcinoma: what lies beyond RET? <i>D. Iacovazzo (United Kingdom)</i>
CP4.2 10 min (7+3)	Are cystic parathyroid adenomas in MEN1 related to cinacalcet treatment? <i>T. Cavalli (Italy)</i>
CP4.3 10 min (7+3)	A case report of the youngest-ever reported malignancy in multiple endocrine neoplasia type 1 <i>M. Lewis (USA)</i>
CP4.4 10 min (7+3)	Maxillary myxomas associated with MEN1 syndrome <i>D. Lourenço (Brazil)</i>
CP4.5 10 min (7+3)	Interdisciplinary treatment of a high malignant gastric neuroendocrine carcinoma (NEC) with hepatic metastasis in multiple endocrine neoplasia type I syndrome: a case report <i>F. Watzka (Germany)</i>
15:00 – 15:25	Jakob Erdheim Honorary Lecture
L2.1 5 min	Introduction <i>B. Niederle (Austria)</i>
L2.2 20 min	Monoclonality, polyclonality, and coupling in MEN1 and other endocrine tumors <i>S.J. Marx (USA)</i>
15:25 – 15:30	Break



Chair S. Baumgartner-Parzer (Austria)
R.F. Gagel (USA)
F. Raue (Germany)

15:30 - 17:30

Session 5
MEN 2 and rare RET mutations / Medullary thyroid cancer

The clinical case discussion

S5.1 5 min **Clinical data**
F. Raue/R. F. Gagel (Germany/USA)

TED - 1
Diagnostic perspectives

S5.2 10 min (7+3) **Cytological, biochemical and molecular findings**
R. Elisei (Italy)

S5.3 10 min (7+3) **Functional Imaging**
G. Treglia (Switzerland)

Treatment perspectives

S5.4 15 min (10+5) **Surgical perspectives**
H. Dralle (Germany)

S5.5 8 min (5+3) **Medical perspectives** (see also S7.2)
R. F. Gagel (USA)

TED – 2
Discussion

S5.6 15 min (10+5) **New developments in the guidelines for management of MEN 2 and medullary thyroid carcinoma**
K. Frank-Raue (Germany), S. A. Wells (USA)

FP5.1 10 min (7+3) **Hereditary medullary thyroid cancer, a comparative study in a Spanish reference care center**
J. Díaz Pérez (Spain)

FP5.2 10 min (7+3) **Long term parathyroid function following total parathyroidectomy with autotransplantation in adult patients with Multiple Endocrine Neoplasia (MEN)**
T. Imai (Japan)

FP5.3 10 min (7+3) **Medullary Thyroid Carcinoma in patients with MEN 2B in Norway. Clinical course of an orphan disease**
E.M. Opsahl (Norway)

FP5.4 10 min (7+3) **Intronic changes in our patients with Medullary Thyroid Carcinoma MTC**
B. Peric (Slovenia)

17:30 – 17:50

Coffee break



Chair		S.J. Marx (USA) I. Virgolini (Austria) B. Wiedenmann (Germany)
17:50 - 19:00		Session 6 New experimental and clinical developments
S6.1	15 min (10+5)	Nuclear RET Increases Survival by Suppression of ATF4-mediated Apoptosis <i>R. Yarmand (USA)</i>
S6.2	15 min (10+5)	Molecular profiling of intestinal NET: future application <i>M.S. Banck (USA)</i>
S6.3	10 min (7+3)	Epigenetic regulation of Hedgehog signaling in MEN1 tumor syndrome. <i>X. Hua (USA)</i>
FP6.1	10 min (7+3)	Chemoprevention with Enalapril and ASS prolongs survival through the AT1-Receptor and NFkB in a transgenic mouse model for islet cell tumors <i>Jens Waldmann (Germany)</i>
FP6.2	10 min (7+3)	Gender-related differences in MEN1 lesion: analysis of 560 cases from the database of the MEN Consortium of Japan <i>M. Katai (Japan)</i>
20:00		Evening Event *

* for detailed information please see page 38



Chair	B. Eriksson (Sweden) R.F. Gagel (USA) B. Wiedenmann (Germany)
08:00 - 10:00	Session 7 Treatment of advanced endocrine tumors
S7.1 20 min (15+5)	Treatment landscape of NET <i>M. Pavel (Germany)</i>
FP7.1 10 min (7+3)	Streptozocin and 5-fluorouracil treatment of pancreatic neuroendocrine tumors: efficacy, toxicity and prognostic factors <i>B. Eriksson (Sweden)</i>
	Advanced medullary thyroid carcinoma: Integration of tyrosine kinase therapy into treatment regimens Vandetanib and Cabozantinib – Competition or completion
S7.2 15 min (10+5)	Vandetanib - Current perspectives <i>R.F. Gagel (USA)</i>
S7.3 15 min (10+5)	Cabozantinib - Current perspectives <i>R. Elisei (Italy)</i>
FP7.2 10 min (7+3)	Treatment with sorafenib in progressive metastatic medullary thyroid cancer (MTC) is well tolerated and is associated with symptom and tumor control <i>L.A. Castroneves (Brazil)</i>
S7.4 20 min (15+5)	Current aspects of a personalized treatment approach in advanced adrenocortical cancer <i>J. Bertherat (France)</i>
FP7.3 10 min (7+3)	Paraganglioma and pheochromocytoma: A difference in disease behaviour and clinical outcomes <i>T. Ezzat Abdel-Aziz (United Kingdom)</i>
10:00 - 10:30	Coffee break



Chair	P. Riss (Austria) A. Selberherr (Austria)
10:30 – 11:30	Session 8 Selected Poster Presentation
SP8.1 10 min (7+3)	Culture of human neuroendocrine tumor cells and xenografts - old and new problems <i>R. Pfragner (Austria)</i>
SP8.2 10 min (7+3)	The CYS634ARG (C634R) mutation provides more aggressiveness to the MEN 2A syndrome <i>J. Rodriguez (Spain)</i>
SP8.3 10 min (7+3)	Follow-up of ≤ 2 cm non functioning pancreatic NETs in patients with MEN 1 treated with conservative approach <i>M.V. Davi' (Italy)</i>
SP8.4 10 min (7+3)	Characteristics of 'foregut' carcinoid tumours occurring in multiple endocrine neoplasia type 1 (MEN 1) <i>L. Yang (United Kingdom)</i>
SP8.5 10 min (7+3)	Potential benefits of a multinational patient alliance to patients with MEN <i>J. Grey (United Kingdom)</i>
SP8.6 10 min (7+3)	Breast cancer predisposition in multiple endocrine neoplasia type 1 (see abstract "P10") <i>K. Dreijerink (USA/The Netherlands)</i>



Chair	B.G. Robinson (Australia) V. Stepan (Austria) C.A. Stratakis (USA)
11:30 - 13:30	Session 9 Hereditary pheochromocytoma and paraganglioma
S9.1 20 min (15+5)	Carney-Stratakis dyad and Carney Triad: an update <i>C.A. Stratakis (USA)</i>
FP9.1 10 min (7+3)	Definition of a new algorithm for molecular-genetic testing of patients with hereditary pheochromocytoma and paraganglioma syndromes <i>T. Musholt (Germany)</i>
S9.2 15 min (10+5)	The role of imaging in screening for pheochromocytoma and paraganglioma <i>R. Hicks (Australia)</i>
S9.3 15 min (10+5)	Clinical experience from the French paraganglioma network (PGL.EVA study) <i>Ch. Lepoutre (France)</i>
S9.4 15 min (10+5)	A new paraganglioma-polycythemia syndrome: Clinical presentations, genetics, and pathogenesis <i>K. Pacak (USA)</i>
S9.5 15 min (10+5)	Malignant hereditary pheochromocytoma and paraganglioma: focus on therapeutics <i>E. Baudin (France)</i>
FP9.2 10 min (7+3)	Validation of immunohistochemistry for SDHB in assessment of germline mutations in pheochromocytoma/paraganglioma (PGG/PCC) syndrome <i>J. Ares (Spain)</i>
13:30 - 14:00	Closing Ceremony * Poster award/Best presentation award
14:00 - 14:30	Farewell

* for detailed information please see page 35



Thursday, September 25, 2014

Congress Venue
Gesellschaft der Ärzte in Wien - Billrothhaus
Frankgasse 8, A-1090 Wien

17:45 – 18:15 Opening Ceremony

F. Chopin - Polonaise A-major, op. 40/1
Th. Bachleitner-Hofmann (Vienna)

Welcome
B. Niederle (Vienna)
Chairman Local Organizing Committee

World Men Award 2014
- lifetime achievement award honoring the lifework to S. A. Wells (USA)
In the name of the International Scientific Committee
R. F. Gagel (USA)

J. S. Bach - Gavotte I & II from English Suite g-minor, BWV 808
Th. Bachleitner-Hofmann (Vienna)

18:15 – 20:00 Welcome Reception / Poster Party

Congress Venue
Gesellschaft der Ärzte in Wien – Billrothhaus
Society of Physicians in Vienna – Billroth House
Frankgasse 8, Vienna A-1090

Struggling with the management of infectious diseases and malnutrition, first attempts to unify the Viennese physicians were undertaken around the beginning of the 19th century. From then on, the rapid distribution of medical information was facilitated by the introduction of printed Annual Medical reports for the inhabitants of Vienna, which later (1887) were followed by the classical journal "Wiener Klinische Wochenschrift".

In 1838, the Society of Physicians was officially founded on the occasion of a festive event with Minister of State Prince von Metternich and the entire medical faculty. Ever since, the Society has been a pacemaker – initially in improving hygiene standards including fresh water supply for the city of Vienna, and today in the advancement of novel treatments based on controlled clinical studies.

The Society of Physicians was originally settled within the building of the old university in the city of Vienna, Dr. Ignaz Seipel Platz 2, where the Austrian Academy of Sciences currently resides. In 1893, following efforts of the Society's then-president Theodor Billroth, an own home base was founded in Frankgasse No. 8, adjacent to the old university clinic "Allgemeines Krankenhaus". This house has since been known as the "Billrothhaus", an important foster place for medical science:

Novel findings were (and still are) presented to the academy in weekly sessions, often rendering hot and critical discussions. The most prestigious personalities in the history of medicine have presented their work for the first time in this place, among them Rokitsansky, Hebra, Freud, Billroth and Landsteiner. They all were pioneers at their time and their findings indeed still impact today's art of medicine.

A unique mark of this architecturally and historically fascinating house is the large meeting room sketched by Billroth himself. Allowing the physicians to leave the hall to attend consultations as rapidly as possible, a total of 21 doors were installed – two side doors for each tier. The hall with 300 seats and a gallery is decorated with portraits of grand physicians and presidents of the Society.

The principal facility of the Billroth House and the actual treasure of the Society of the Physicians is its library. With approximately 25,000 monographs and 2,000 historically valuable journals, it ranks today among the most prized specialist libraries of the world. Only few collections incorporate comparable complete sets of publications, going back a hundred and more years. Containing Billroth's entire official and private correspondence, amongst others, the extensive archives were relocated to the Institute for the History of Medicine in the Josephinum.

For the friends of old libraries, one highlight is the reading room, albeit a dangerous one: an area in which one may forget time and spend hours browsing through the treasury.



© Billrothhaus